Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials

Phase I Clinical Trials ◽

Two Phase ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival

European Journal of Nuclear Medicine and Molecular Imaging ◽

10.1007/s00259-016-3543-x ◽

2016 ◽

Vol 44 (4) ◽

pp. 620-629 ◽

Cited By ~ 11

Author(s):

Ana M. Denis-Bacelar ◽

Sarah J. Chittenden ◽

David P. Dearnaley ◽

Antigoni Divoli ◽

Joe M. O’Sullivan ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Post Hoc ◽

The Impact ◽

Administered Activity

Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials

Clinical & Translational Oncology ◽

10.1007/s12094-020-02334-6 ◽

2020 ◽

Vol 22 (11) ◽

pp. 2126-2129 ◽

Cited By ~ 1

Author(s):

A. Carretero-González ◽

D. Lora ◽

R. Manneh ◽

D. Lorente ◽

D. Castellano ◽

...

Keyword(s):

Prostate Cancer ◽

Vitamin D ◽

Clinical Trials ◽

Randomized Clinical Trials ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302

European Urology ◽

10.1016/j.eururo.2015.04.032 ◽

2015 ◽

Vol 68 (4) ◽

pp. 570-577 ◽

Cited By ~ 33

Author(s):

Fred Saad ◽

Neal Shore ◽

Hendrik Van Poppel ◽

Dana E. Rathkopf ◽

Matthew R. Smith ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Targeted Therapies ◽

Abiraterone Acetate ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Combination of body mass index and albumin predicts the survival in metastatic castration‐resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials

Cancer Medicine ◽

10.1002/cam4.4205 ◽

2021 ◽

Author(s):

Jian Pan ◽

Jun Wang ◽

Yu Wei ◽

Tingwei Zhang ◽

Sheng Zhang ◽

...

Keyword(s):

Prostate Cancer ◽

Body Mass Index ◽

Cancer Patients ◽

Body Mass ◽

Randomized Trials ◽

Post Hoc Analysis ◽

Castration Resistant ◽

The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients

Investigative and Clinical Urology ◽

10.4111/icu.2016.57.3.174 ◽

2016 ◽

Vol 57 (3) ◽

pp. 174 ◽

Cited By ~ 11

Author(s):

Choung-Soo Kim ◽

Ad Theeuwes ◽

Dong Deuk Kwon ◽

Young Deuk Choi ◽

Byung Ha Chung ◽

...

Keyword(s):

Prostate Cancer ◽

Post Hoc Analysis ◽

Korean Patients ◽

Castration Resistant ◽

Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry

Annals of Oncology ◽

10.1093/annonc/mdy284.027 ◽

2018 ◽

Vol 29 ◽

pp. viii284-viii285

Author(s):

Z. Malik ◽

A. Pichler ◽

G. Di Lorenzo ◽

U. De Giorgi ◽

S. Hitier ◽

...

Keyword(s):

Prostate Cancer ◽

Treatment Duration ◽

Compassionate Use ◽

Post Hoc Analysis ◽

Expanded Access ◽

Castration Resistant ◽

Baseline Characteristics ◽

Post Hoc ◽

Access Programs

Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4678 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4678-4678 ◽

Cited By ~ 3

Author(s):

S. Nilsson ◽

C. Parker ◽

I. Haugen ◽

A. Lokna ◽

A. Aksnes ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase I ◽

Bone Metastases ◽

Safety Profile ◽

Combined Analysis ◽

Castration Resistant ◽

Radium 223 ◽

Phase I And Ii

668 Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302

European Urology Supplements ◽

10.1016/s1569-9056(15)60661-3 ◽

2015 ◽

Vol 14 (2) ◽

pp. e668-e668a ◽

Cited By ~ 1

Author(s):

F. Saad ◽

J.S. De Bono ◽

M.R. Smith ◽

D.E. Rathkopf ◽

P.F.A. Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Taxane Chemotherapy ◽

Open-label, phase I, dose escalation study to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E (GEN0101) in castration-resistant prostate cancer patients

European Urology Supplements ◽

10.1016/s1569-9056(19)30876-0 ◽

2019 ◽

Vol 18 (1) ◽

pp. e1220

Author(s):

K. Fujita ◽

Y. Nakai ◽

D. Kato ◽

A. Kawashima ◽

T. Ujike ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Cancer Patients ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽

Safety And Efficacy ◽

Castration Resistant ◽

Open Label Phase

New Peptide-Based Cancer Vaccine: Phase I and Early Phase II Clinical Trials for Castration-Resistant Prostate Cancer

Annals of Oncology ◽

10.1016/s0923-7534(20)32150-5 ◽

2012 ◽

Vol 23 ◽

pp. xi74

Author(s):

Masanori Noguchi ◽

Shigetaka Suekane ◽

Fukuko Moriya ◽

Tetsuro Sasada ◽

Akira Yamada ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase I ◽

Phase Ii ◽

Cancer Vaccine ◽

Early Phase ◽

Castration Resistant ◽

Phase Ii Clinical Trials